Stem Cell Therapy for Peripheral Neuropathy: What the Early Evidence Shows

Peripheral neuropathy — numbness, tingling, burning pain, and weakness in the hands and feet — affects an estimated 20 million Americans. Diabetic neuropathy alone accounts for roughly half of all cases, but chemotherapy-induced, idiopathic, and autoimmune neuropathies drive substantial patient demand for treatment options beyond current pharmacological management. Stem cell therapy is generating interest in this space, but the evidence requires careful, honest framing.

The Biological Rationale

MSCs have properties that are theoretically relevant to neuropathy. Published preclinical research shows they can reduce neuroinflammation (a key driver of neuropathic pain), secrete neurotrophic factors (BDNF, NGF, GDNF) that support nerve survival and repair, promote angiogenesis (new blood vessel formation) that improves nerve blood supply, and modulate the immune response in autoimmune neuropathies. These mechanisms are demonstrated in laboratory and animal studies. The translation to human clinical benefit remains unproven.

What MSC Therapy May Do

Patient reports (anecdotal, Level 4 evidence) and very small case series suggest some patients experience reduced neuropathic pain (burning, tingling), modestly improved sensation in affected areas, improved nerve conduction velocity on electrodiagnostic testing (in a few published case reports), and better quality-of-life scores. These reports are encouraging but must be interpreted cautiously — placebo response rates in neuropathy studies are notoriously high (30-40%), and without controlled studies, it is impossible to separate MSC effect from placebo.

What MSC Therapy Cannot Do

It is critical to set expectations clearly. MSC therapy cannot reverse established structural nerve death (axonal degeneration that has progressed to the point of permanent fiber loss), restore sensation in areas where nerves have been completely destroyed, cure the underlying cause of neuropathy (patients with diabetic neuropathy must still manage their diabetes; chemotherapy-induced neuropathy management must continue alongside any regenerative approach), or guarantee improvement — even in the best-case scenario, response rates in early data are nowhere near 100%.

Treatment Protocol

Neuropathy protocols in Colombia typically involve systemic IV MSC infusion (to deliver anti-inflammatory and neurotrophic factors throughout the body) sometimes combined with localized injections near affected nerve pathways. Treatment courses may involve one to three sessions over one to two weeks. Pricing ranges from $8,000 to $15,000 depending on the protocol complexity and number of sessions.

Who Might Reasonably Consider This Treatment

At Level 4 evidence, MSC therapy for neuropathy is most appropriate for patients who have exhausted conventional options (gabapentin, pregabalin, duloxetine, topical treatments, physical therapy), understand and accept the experimental nature of the treatment, have the financial resources to invest in an unproven therapy, are working with a neurologist at home who is aware of and supportive of their decision, and can return for follow-up assessments to track objective measures (nerve conduction studies, quantitative sensory testing).